Haloperidol Tablets Rx
Generic Name and Formulations:
Haloperidol 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg; scored tabs.
Various generic manufacturers
Indications for Haloperidol Tablets:
Psychosis. Tourette's disorder. For severe behavior disorders or as a short-term treatment for hyperactivity in children who are refractory to psychotherapy or other medications.
Individualize. Initially: Moderate symptoms: 0.5mg–2mg 2–3 times daily. Severe, chronic, or resistant symptoms: 3mg–5mg 2–3 times daily. Debilitated: 0.5mg–2mg 2–3 times daily. Max: 100mg/day.
<3yrs: not recommended. Total dose may be divided, to be given 2–3 times daily. ≥3yrs: initially 0.5mg daily, may increase at increments of 0.5mg at 5–7 day intervals. Psychosis: 0.05mg/kg/day–0.15mg/kg/day. Nonpsychotic behavior and Tourette's: 0.05mg/kg/day–0.075mg/kg/day. Max 6mg/day.
Initially 0.5mg–2mg 2–3 times daily.
Severe CNS depression. Coma. Parkinsonism.
Increased mortality in elderly patients with dementia-related psychosis.
Elderly with dementia-related psychosis (not approved use): increased risk of death. Risk of QT prolongation: electrolyte disturbances (eg, hypokalemia, hypomagnesemia), underlying cardiac abnormalities, hypothyroidism, familial long QT-syndrome, concomitant drugs known to prolong the QT interval. Seizures. Thyrotoxicosis. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Severe cardiovascular disorders. Mania. Avoid abrupt cessation. Debilitated. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers: not recommended.
CNS depression potentiated with alcohol, other CNS depressants. Possible neurotoxicity with lithium: monitor, discontinue if occurs. Caution with drugs that prolong the QT interval (eg, ketoconazole, paroxetine). May be potentiated by CYP3A4 inhibitors/substrates or CYP2D6 enzymes (eg, itraconazole, nefazodone, buspirone, venlafaxine, alprazolam, fluvoxamine, quinidine, fluoxetine, sertraline, chlorpromazine, promethazine. May be antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine); monitor and adjust doses. May increase intraocular pressure with anticholinergics. Monitor anticoagulants.
Tardive dyskinesia, extrapyramidal symptoms, CNS effects, GI upset, cardiovascular effects, bronchopneumonia, neuroleptic malignant syndrome.
Formerly known under the brand name Haldol.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Tools to Address the Opioid Crisis
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Nonsinogenic Headache vs Chronic Rhinosinusitis Differential Diagnosis Based on SNOT-22 Patterns
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Factors Promoting Participation in Self-Management Training Program for Chronic Pain
- Gendered Perceptions of Socially Acceptable Pain Relief Strategies
- Majority of Internists Still Have Financial Ties to Industry